At Applied BioAnalytics we know that each therapeutic is unique, as are the teams developing them. Your team and your therapeutics in particular. We offer personalized and comprehensive services based on industrial standard procedures and detailed knowledge of regulatory requirements. Our staff’s expertise includes but is not limited to:
Your source for new & improved methods, including qualification
▪ Size heterogeneity and purity assessment via CE-SDS and CE(SDS)-MS
– Including the use of our flat baseline CE-SDS gel
▪ Charge heterogeneity analysis via cIEF
▪ Charge variant analysis via CZE
▪ Quantitative monosaccharide analysis via CE-LIF
▪ Quantitative sialic acid speciation via CE-LIF
▪ Exoglycosidase mediated glycan sequencing /mapping via CE-LIF
▪Viral vector purity, empty/full, and quantification via CGE
Example 1 –
High resolution glycan profiling
N-glycan composition profiling is essential for quality testing of biotherapeutics because the glycan structure is designated as a critical quality attribute (CQA) that must be monitored during manufacturing. The glycan profile of a finished product is used to assess the consistency of a manufacturing process from batch to batch. Our capillary electrophoresis separation-based glycan profiling technology enables extraordinary resolution, which cannot be addressed by LC methods alone.
Example 2 –
Automated carbohydrate sequencing
In addition to high resolution glycosylation profiling, carbohydrate sequencing is an important part of bioprocess analysis, especially when clients have unknown peaks in their sample. In glycan sequencing, carbohydrates are sequentially digested by various linkage-specific exoglycosidase enzymes allowing complete, high confidence structural elucidation for biological-relevance exploration or structural identity confirmation. Our in-house developed and validated semi- and fully automated sequencing methods ensure robust and fast service not available from other companies.
Example 3 –
Purity and heterogeneity measurements & demonstrative measurement results
Precise determination of low-level impurities of biologics is a challenging bioanalytical task through the entire biologics and biosimilar development pipeline. Biopharma analytical laboratories require quantitative and validated data, which is exactly what Applied Bio-Analytics offers via utilization of the CE-SDS-MW method, which allows for the resolution of reduced and non-reduced mAb’s by size and to subsequently quantify the heterogeneity and impurities that may be present in mAb preparations. High quality CE-SDS data provides the critical confidence required for right decision-making – not necessarily available using other technologies. High reproducibility of our CE-SDS-MW measurement was confirmed by a 6-day trial with six runs per day using our internal standard monoclonal antibody sample. Our optimized methods offer excellent relative standard deviation (RSD) values for HC peak %Corrected area (under 0.2%), which is below the RSD value reported by the vendor of the kit used (see Figure 1 and Table).
Sarkozy D, Guttman A. Analysis of Peptides and Proteins by Native and SDS Capillary Gel Electrophoresis Coupled to Electrospray Ionization Mass Spectrometry via a Closed-Circuit Coaxial Sheath Flow Reactor Interface. Anal Chem. 2023 May 9;95(18):7082-7086. doi: 10.1021/acs.analchem.2c04332.
Figure 1. SDS-MW separation of Daratumumab mAb sample
Daratumumab mAb sample
Example 4 –
Charge variant and
charge heterogeneity analysis &
demonstrative measurement results
Working with biologics, especially with mAbs, requires information on different charge variants to determine identity and stability. Post-production analysis by cIEF can give information about purity, stability, and post-translational modifications of therapeutic proteins. By capillary isoelectric focusing (cIEF) we offer our clients ultra-high resolution charge heterogeneity data. cIEF is inherently consistent allowing global assessment, which is critical to both R&D and meeting regulatory requirements.
Figure 2. cIEF analysis of Daratumumab mAb sample with CE
Method Development Request
Request a meeting to discuss how AB can help you with your next method development project here: